STATE HIGHER EDUCATIONAL ESTABLISHMENT «UZHHOROD NATIONAL UNIVERSITY», UZHHOROD, UKRAINE.
Wiad Lek. 2023;76(3):581-585. doi: 10.36740/WLek202303119.
The aim: To evaluate the effectiveness of the proposed treatment recommendations, which included lifestyle changes, as well as the treatment with ursode¬oxycholic acid, rosuvastatin, and omega-3 PUFA, on the severity of cytolytic and cholestatic syndromes in patients with NAFLD and prediabetes.
Materials and methods: Fifty-five patients with confirmed prediabetes and concomitant NAFLD underwent a comprehensive clinical examination and were treated with rosuvastatin 10 mg/d, omega-3 PUFA at a dose of 1000 mg/d and ursodeoxycholic acid at a dose of 10 mg/kg/d.
Results: The data obtained after 12 months of proposed treatment revealed a statistically significant improvement of indicators of cytolytic syndrome in patients with prediabetes and NAFLD. There was no significant difference between mean values of ALT and AST of treated patients and the corresponding indicators of apparently healthy persons, which confirms the effectiveness of the recommended treatment.
Conclusions: Proposed therapy which included recommendations for lifestyle changes and treatment with ursodeoxycholic acid, rosuvastatin and omega-3 PUFA significantly improved hepatic steatosis and cytolytic syndrome in patients with prediabetes and NAFLD.
评估所提出的治疗建议的有效性,这些建议包括生活方式的改变,以及使用熊去氧胆酸、瑞舒伐他汀和欧米伽-3 PUFA 的治疗,对非酒精性脂肪性肝病和糖尿病前期患者的细胞溶解和胆汁淤积综合征的严重程度的影响。
材料和方法:55 名确诊为糖尿病前期且伴有非酒精性脂肪性肝病的患者接受了全面的临床检查,并接受了瑞舒伐他汀 10 毫克/天、欧米伽-3 PUFA 1000 毫克/天和熊去氧胆酸 10 毫克/公斤/天的治疗。
结果:经过 12 个月的建议治疗后,获得的数据显示,糖尿病前期和非酒精性脂肪性肝病患者的细胞溶解综合征指标有统计学意义的改善。治疗患者的 ALT 和 AST 的平均值与明显健康人的相应指标之间没有显著差异,这证实了所建议的治疗的有效性。
结论:包括生活方式改变建议以及使用熊去氧胆酸、瑞舒伐他汀和欧米伽-3 PUFA 的治疗方案,显著改善了糖尿病前期和非酒精性脂肪性肝病患者的肝脂肪变性和细胞溶解综合征。